Management of Impaired Carbohydrate Metabolism - A Review
DOI:
https://doi.org/10.12775/QS.2025.42.61233Keywords
Iatrogenic Cushing Syndrome, hypercortisolism, glucocorticoids, adverse effects, carbohydrate metabolism, glucocorticoid-induced hyperglycemia, hyperglycemia, glucocorticoid-induced diabetesAbstract
Introduction and purpose: Cushing Syndrome is a condition associated with a long-term elevated concentration of cortisol in the circulatory system. The most common type of Cushing syndrome is exogenous hypercortisolism, primarily iatrogenic, resulting from long-term glucocorticoid use, which affects multiple biological systems, including carbohydrate metabolism. The aim of our work was to present the mechanisms by which glucocorticoids affect carbohydrate metabolism and compile information on strategies for its management.
Background: Glucocorticoids disrupt carbohydrate metabolism causing increased hyperglycemia, insulin resistance and diabetes mellitus. These adverse effects result from increased hepatic gluconeogenesis, reduced glycogenolysis, decreased expression of glucose transporter type 4 (GLUT4) and impaired insulin signaling. The most important factor to reduce the impact of glucocorticoids on carbohydrate metabolism is optimization of glucocorticoid therapy and ensuring proper patient surveillance. A comprehensive medical history and physical examination should be conducted prior to administration of long-term glucocorticoid therapy, with regular blood glucose monitoring throughout treatment. Another key factor is prompt implementation of appropriate pharmacologic therapy. Basal bolus insulin therapy is recommended for managing glucocorticoid-induced hyperglycemia (GIH), with metformin as the preferred oral agent. Equally significant is adopting a balanced diet and regular physical activity.
Conclusion: Iatrogenic Cushing syndrome pose a significant problem both for patients and healthcare providers. Studies outline strategies for management of glucocorticoid-induced impaired carbohydrate metabolism, however further research is required to develop evidence-based guidelines to validate and optimize these approaches and improve the quality of life in patients with iatrogenic Cushing syndrome.
References
1. Chaudhry HS, Singh G. Cushing Syndrome. [Updated 2023 Jun 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470218/
2. Nieman LK. Recent Updates on the Diagnosis and Management of Cushing's Syndrome. Endocrinol Metab (Seoul). 2018 Jun;33(2):139-146. doi: 10.3803/EnM.2018.33.2.139. PMID: 29947171; PMCID: PMC6021313.
3. Lodish MB, Keil MF, Stratakis CA. Cushing's Syndrome in Pediatrics: An Update. Endocrinol Metab Clin North Am. 2018 Jun;47(2):451-462. doi: 10.1016/j.ecl.2018.02.008. PMID: 29754644; PMCID: PMC5962291.
4. Hoenig LJ. The Buffalo Hump of Cushing Syndrome. Clin Dermatol. 2022 Sep-Oct;40(5):617-618. doi: 10.1016/j.clindermatol.2021.08.018. Epub 2021 Aug 18. PMID: 36509510.
5. Savas M, Mehta S, Agrawal N, van Rossum EFC, Feelders RA. Approach to the Patient: Diagnosis of Cushing Syndrome. J Clin Endocrinol Metab. 2022 Nov 23;107(11):3162-3174. doi: 10.1210/clinem/dgac492. PMID: 36036941; PMCID: PMC9681610.
6. Uwaifo GI, Hura DE. Hypercortisolism. [Updated 2023 Jul 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551526/
7. Pivonello R, Ferrigno R, De Martino MC, Simeoli C, Di Paola N, Pivonello C, Barba L, Negri M, De Angelis C, Colao A. Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials. Front Endocrinol (Lausanne). 2020 Dec 8;11:648. doi: 10.3389/fendo.2020.00648. PMID: 33363514; PMCID: PMC7753248.
8. Cai Y, Ren L, Tan S, Liu X, Li C, Gang X, Wang G. Mechanism, diagnosis, and treatment of cyclic Cushing's syndrome: A review. Biomed Pharmacother. 2022 Sep;153:113301. doi: 10.1016/j.biopha.2022.113301. Epub 2022 Jun 17. PMID: 35717778.
9. Becker DE. Basic and clinical pharmacology of glucocorticosteroids. Anesth Prog. 2013 Spring;60(1):25-31; quiz 32. doi: 10.2344/0003-3006-60.1.25. PMID: 23506281; PMCID: PMC3601727.
10. Horby, P., Lim, W. S., Emberson, J. R., Mafham, M., Bell, J. L., Linsell, L., ... & Landray, M. J. (2021). RECOVERY Collaborative Group Dexamethasone in hospitalized patients with Covid-19. N Engl J Med, 384(8), 693-704. doi: 10.1056/NEJMoa2021436
11. Bjornsdottir HH, Einarsson ÓB, Gröndal G, Gudbjornsson B. Nationwide prevalence of glucocorticoid prescriptions over 17 years and osteoporosis prevention among long-term users. SAGE Open Med. 2024 Mar 20;12:20503121241235056. doi: 10.1177/20503121241235056. PMID: 38516640; PMCID: PMC10956150.
12. Wallace BI, Tsai HJ, Lin P, et al. Prevalence and prescribing patterns of oral corticosteroids in the United States, Taiwan, and Denmark, 2009-2018. Clin Transl Sci 2023; 16(12): 2565–2576. https://doi.org/10.1111/cts.13649
13. Sharma ST, Nieman LK. Cushing's syndrome: all variants, detection, and treatment. Endocrinol Metab Clin North Am. 2011 Jun;40(2):379-91, viii-ix. doi: 10.1016/j.ecl.2011.01.006. PMID: 21565673; PMCID: PMC3095520.
14. Kumar, S. , Kumar, S. , Khanduri, S. , Jethani, V. , Kumar, M. and Khanduri, R. Sodhi (2021). Prevalence of Clinical Iatrogenic Cushing’s Syndrome and its Contributing Factors in Patients with Chronic Obstructive Airway Disease. Journal of Cardio-Thoracic Medicine, 9(4), 884-890. doi: 10.22038/jctm.2021.59462.1347
15. Cho JH, Suh S. Glucocorticoid-Induced Hyperglycemia: A Neglected Problem. Endocrinol Metab (Seoul). 2024 Apr;39(2):222-238. doi: 10.3803/EnM.2024.1951. Epub 2024 Mar 27. PMID: 38532282; PMCID: PMC11066448.
16. Barker HL, Morrison D, Llano A, Sainsbury CAR, Jones GC. Practical Guide to Glucocorticoid Induced Hyperglycaemia and Diabetes. Diabetes Ther. 2023 May;14(5):937-945. doi: 10.1007/s13300-023-01393-6. Epub 2023 Mar 24. PMID: 36961675; PMCID: PMC10037401.
17. Dutt M, Wehrle CJ, Jialal I. Physiology, Adrenal Gland. [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537260/
18. Timmermans S, Souffriau J, Libert C. A General Introduction to Glucocorticoid Biology. Front Immunol. 2019 Jul 4;10:1545. doi: 10.3389/fimmu.2019.01545. PMID: 31333672; PMCID: PMC6621919.
19. Ramamoorthy S, Cidlowski JA. Corticosteroids: Mechanisms of Action in Health and Disease. Rheum Dis Clin North Am. 2016 Feb;42(1):15-31, vii. doi: 10.1016/j.rdc.2015.08.002. PMID: 26611548; PMCID: PMC4662771.
20. Mitre-Aguilar IB, Cabrera-Quintero AJ, Zentella-Dehesa A. Genomic and non-genomic effects of glucocorticoids: implications for breast cancer. Int J Clin Exp Pathol. 2015 Jan 1;8(1):1-10. PMID: 25755688; PMCID: PMC4348864.
21. Paragliola, R. M., Papi, G., Pontecorvi, A., & Corsello, S. M. (2017). Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis. International Journal of Molecular Sciences, 18(10), 2201. https://doi.org/10.3390/ijms18102201
22. Li JX, Cummins CL. Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. Nat Rev Endocrinol. 2022 Sep;18(9):540-557. doi: 10.1038/s41574-022-00683-6. Epub 2022 May 18. PMID: 35585199; PMCID: PMC9116713.
23. Beaupere C, Liboz A, Fève B, Blondeau B, Guillemain G. Molecular Mechanisms of Glucocorticoid-Induced Insulin Resistance. Int J Mol Sci. 2021 Jan 9;22(2):623. doi: 10.3390/ijms22020623. PMID: 33435513; PMCID: PMC7827500.
24. Sanpawithayakul K, Korbonits M. Metabolic complications of glucocorticoids - Prevention by metformin. Ann Endocrinol (Paris). 2023 Aug;84(4):483-497. doi: 10.1016/j.ando.2023.05.002. Epub 2023 May 18. PMID: 37209947.
25. Pofi R, Caratti G, Ray DW, Tomlinson JW. Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad? Endocr Rev. 2023 Nov 9;44(6):975-1011. doi: 10.1210/endrev/bnad016. PMID: 37253115; PMCID: PMC10638606.
26. Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, Brown JP, Cohen A, Kim H. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013 Aug 15;9(1):30. doi: 10.1186/1710-1492-9-30. PMID: 23947590; PMCID: PMC3765115.
27. Shah P, Kalra S, Yadav Y, Deka N, Lathia T, Jacob JJ, Kota SK, Bhattacharya S, Gadve SS, Subramanium KAV, George J, Iyer V, Chandratreya S, Aggrawal PK, Singh SK, Joshi A, Selvan C, Priya G, Dhingra A, Das S. Management of Glucocorticoid-Induced Hyperglycemia. Diabetes Metab Syndr Obes. 2022 May 23;15:1577-1588. doi: 10.2147/DMSO.S330253. PMID: 35637859; PMCID: PMC9142341.
28. Roberts A, James J, Dhatariya K; Joint British Diabetes Societies (JBDS) for Inpatient Care. Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. Diabet Med. 2018 Aug;35(8):1011-1017. doi: 10.1111/dme.13675. PMID: 30152586.
29. Brooks D, Schulman-Rosenbaum R, Griff M, Lester J, Low Wang CC. Glucocorticoid-Induced Hyperglycemia Including Dexamethasone-Associated Hyperglycemia in COVID-19 Infection: A Systematic Review. Endocr Pract. 2022 Nov;28(11):1166-1177. doi: 10.1016/j.eprac.2022.07.014. Epub 2022 Aug 5. PMID: 35940469; PMCID: PMC9354392.
30. Pernicova I, Kelly S, Ajodha S, Sahdev A, Bestwick JP, Gabrovska P, Akanle O, Ajjan R, Kola B, Stadler M, Fraser W, Christ-Crain M, Grossman AB, Pitzalis C, Korbonits M. Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. Lancet Diabetes Endocrinol. 2020 Apr;8(4):278-291. doi: 10.1016/S2213-8587(20)30021-8. Epub 2020 Feb 25. PMID: 32109422.
31. Willi SM, Kennedy A, Brant BP, Wallace P, Rogers NL, Garvey WT. Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes. Diabetes Res Clin Pract. 2002 Nov;58(2):87-96. doi: 10.1016/s0168-8227(02)00127-4. PMID: 12213349.
32. Pasmans K, Meex RCR, van Loon LJC, Blaak EE. Nutritional strategies to attenuate postprandial glycemic response. Obes Rev. 2022 Sep;23(9):e13486. doi: 10.1111/obr.13486. Epub 2022 Jun 10. PMID: 35686720; PMCID: PMC9541715.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Patrycja Podlejska, Katarzyna Rozkosz, Katarzyna Torbacka, Aleksandra Sosin, Wojciech Bednarz, Zuzanna Wróbel, Natalia Wróbel, Olga Jakubik, Maja Torbacka, Joanna Kaczor

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 265
Number of citations: 0